PROM1 and osteosarcoma: One study by Ni et al. designed a drug delivery system (Ap-SAL-NP) for the targeted treatment of osteosarcoma by using CD133, a cancer stem cell (CSCs) marker for osteosarcoma, as an aptamer and conjugating with salinomycin-loaded PEGylated PLGA nanoparticles (Figure 2B).